Clinical Trials
270 trialsTRIFOUR
Cantargia AB
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
LEAP-005
Merck Sharp & Dohme LLC
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
TORCHLIGHT
Shanghai Junshi Bioscience Co., Ltd.
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
NeoSACT
Guangdong Provincial People's Hospital
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Icahn School of Medicine at Mount Sinai
RADIOLA
SOLTI Breast Cancer Research Group
MK-4700-001
Merck Sharp & Dohme LLC
TNBC-MERIT
BioNTech SE
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
KEYLYNK-009
Merck Sharp & Dohme LLC
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
OPALESCENCE
Institut Cancerologie de l'Ouest
FORTITUDE-301
Amgen
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
EL1SSAR
Hoffmann-La Roche
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
A-Brave
Istituto Oncologico Veneto IRCCS
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Seagen Inc.
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
Memorial Sloan Kettering Cancer Center
PRIMED
MedSIR
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Providence Health & Services
RadioPARP
Institut Curie
IMpassion132
Hoffmann-La Roche
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
M.D. Anderson Cancer Center
MK-5890-001
Merck Sharp & Dohme LLC
ROLo
Royal Marsden NHS Foundation Trust
MK-3475-522
Merck Sharp & Dohme LLC
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Hummingbird Bioscience
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Dana-Farber Cancer Institute
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
National Cancer Centre, Singapore
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Institut Curie
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Alliance for Clinical Trials in Oncology
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Takeda
Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
Beni-Suef University
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
KEYVIBE-005
Merck Sharp & Dohme LLC
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
Pure Biologics S.A.
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
TransThera Sciences (Nanjing), Inc.
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients
Sun Yat-sen University
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
Fudan University
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.